- December 20, 2016
- Posted by: cipcadmin
- Category: Events & Tradeshows, News Releases
West Vancouver, British Columbia, December 20, 2016 – Canadian International Pharma Corp. (the “Company” or “CIPC”) – CIPC is pleased to announce that it has received an initial order from Nano Hayat Darou Company (“Nano”), a division of CinnaGen Co. based in Iran, to test a sample under its PharmaCert Program.
This is the initial step for Nano in the PharmaCert process. Once the product has been tested and should it meet all of the criteria, CIPC will provide a PharmaCert certification which assures the manufacturer, distributor, regulator and consumer that the medication adheres to Canadian Good Manufacturing Practices (“GMP”) standards of quality, safety and effectiveness. The Company believes that with a successful testing and certification, Nano intends to place an order under the PharmaCert Program, the size of which will be dependent on the batch produced, and that Nano anticipates multiple neutraceuticals and medications to go through the PharmaCert Program.
PharmaCert is a certification program for finished dosage forms of nutraceutical and pharmaceutical medications. The PharmaCert certification states that the medication has been tested and retested using rigorous and globally respected Canadian or US standards that measure the identity, strength, quality and purity of the medication based on trusted standards, such as United States Pharmacopeia, British Pharmacopeia or other high standard of Pharmacopeia.
About CinnaGen Co.
CinnaGen Co. was founded in 1994 and has grown to become the biggest bio-pharmaceutical manufacturer and biotech exporter in Iran. The company is focused on developing the bio-similar candidates in the areas of immunological diseases, infertility, hormone disorders and oncology as well as providing contract research development services. The Company is spending over 30 percent of its total turnover on R&D activities. It is CinnaGen’s aim to use its expertise to identify and acquire selected products through strategic partnerships to promote sustainable development in human health.
About Canadian International Pharma Corp.
Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales. CIPC has recently launched its PharmaCert Program. PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at www.canpharmacorp.ca.
CANADIAN INTERNATIONAL PHARMA CORP.
Mehrun Payravi, President
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.
FORWARD LOOKING STATEMENTS
This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information. Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.